UK lowers new medicine rebate scheme Read in browser

Thank you for reading, dupa dupackia! basic Subscription UPGRADE

M T Wed Th F 10 December, 2025

See What’s Ahead—Download the 2026 Market Access Trends Report sponsored by Cencora

presented by Pra­tia ac­cel­er­ates U.S. ex­pan­sion with ma­jor­i­ty in­vest­ment in P1 Tri­als, strength­en­ing its glob­al ear­ly-phase on­col­o­gy net­work

news Exclusive: AI unicorn Formation Bio licenses a TYK2 drug from China D3 Bio raises $108M to take next-gen KRAS G12C drug into Phase 3 BlossomHill gets another $84M for macrocyclic approach to EGFR Roivant spinout PsiThera gets $47.5M for oral I&I drugs UK lowers new medicine rebate scheme to 14.5% for 2026

Dec 16 11:30am ET Ensure EU GMP Annex I compliance while maintaining sterile injectable manufacturing excellence & agility sponsored by Grand River Dec 17 12:00pm ET Genetic cohorting and therapeutic response in CKD: Real-world insights from RenasightIQ™ sponsored by Natera

This week: Our latest survey captured the bleakest biotech outlook in a decade — but is recent momentum real or a mirage? Join us to hear what CEOs are saying about the industry’s direction. Sign up now.

ENDPOINTS PHARMA New CAR-T, bispecific data raise questions about sequencing of treatments in multiple myeloma FDA is taking another look at safety of approved RSV antibodies FDA's probe of Covid-19 vaccines expands into adults, led by critic of shots Eli Lilly earmarks $6B for GLP-1 pill factory in Alabama J&J-backed Cellular Origins raises $40M for cell therapy manufacturing  Eli Lilly's Jaypirca makes first-line case in chronic lymphocytic leukemia, but ceiling may be capped

in case you missed it 1. Biotech IPOs might be frozen, but investors are snapping up stock from existing companies 2. Early in vivo CAR-T results like Kelonia's elicit excitement across the field 3. News Briefing Stealthy biotech Sidera Bio raises $109M; Assembly's data for oral herpes drugs 4. Pfizer to pay $150M upfront for small molecule GLP-1 from Fosun subsidiary 5. BioNTech, Bristol Myers unwrap Phase 2 data for PD-L1xVEGF-A bispecific in breast cancer 6. SanegeneBio raises $110M in follow-up to metabolic deal with Lilly